Clinical Resources

May 9, 2014—The purpose of this expert consensus statement is to provide clinicians with guidance on the use of implantable cardioverter-defibrillator (ICD) therapy in the management of some common populations of patients who are not represented in clinical trials and who therefore are not specifically included in the various guidelines that provide indications for ICD therapy. However, recommendations made in this document cannot account for all the nuances of clinical medicine and cannot replace careful clinical judgment for the care of an individual patient. 

 This document was reaffirmed on October 21, 2020, and will be formally assessed by October 2025.

May 9, 2014—This international expert consensus statement was written by experts in the field who were chosen by the Heart Rhythm Society in collaboration with representatives from the American College of Cardiology, American College of Chest Physicians, American Heart Association, Asia Pacific Heart Rhythm Society, European Hear Rhythm Association, and World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG).

May 8, 2014—This expert consensus statement was developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). The purpose of this consensus statement is to define optimal conditions for the delivery of care regarding arrhythmias in adults with congenital heart disease and to provide expert and, where possible, evidence-based recommendations on best practice procedures for the evaluation, diagnosis, and management of arrhythmias, including medical treatment, catheter-based interventions, device therapy, and surgical options.

See also 2016 PACES/HRS Expert Consensus Statement on the Use of Catheter Ablation in Children and Patients with Congenital Heart Disease.

May 8, 2014—This expert consensus statement was developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). The purpose of this consensus statement is to provide up-to-date recommendations on the evaluation and treatment of ventricular tachycardia (VT) in children with structurally normal hearts (idiopathic VT).

See also 2016 PACES/HRS Expert Consensus Statement on the Use of Catheter Ablation in Children and Patients with Congenital Heart Disease.

May 7, 2014—This expert consensus statement was written by experts and developed in collaboration with and endorsed by the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the Pediatric and Congenital Electrophysiology Society (PACES). The goal is to provide physicians, administrators, and regulatory personnel with the recommended requirements for building, staffing, and running a modern EP laboratory to optimize patient outcomes, minimize patient risk, and provide a safe and positive environment for physicians and staff.

 This document was reaffirmed on July 16, 2020, and will be formally assessed by July 2025. 

This expert consensus statement was written by experts and developed in collaboration with and endorsed by the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the Pediatric and Congenital Electrophysiology Society (PACES).  Endorsed by Asia Pacific Heart Rhythm Society (APHRS), European Heart Rhythm Association (EHRA), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)-Latin American Society of Cardiac Pacing and Electrophysiology.

March 28, 2014—The goal of this guideline is to establish revised recommendations for optimum management of atrial fibrillation. The guideline supersedes the 2006 ACC/AHA/ESC Guideline for the Management of Patients with Atrial Fibrillation and the two subsequent focused updates from 2011.

 See 2019 AHA/ACC/HRS Focused Update the scope of which includes revisions to the section on anticoagulant (because of the approval of new medications and thromboembolism protection devices), revisions to the section on catheter ablation of atrial fibrillation (AF), revisions to the section on the management of AF complicating acute coronary syndrome (ACS), and new sections on device detection of AF and weight loss.

September 3, 2013—The objective of the document is to provide clinical guidance for diagnosis, risk stratification, and management of patients affected by inherited primary arrhythmia syndromes. It summarizes the opinion of the international writing group members based on their own experience and on a general review of the literature with respect to the clinical data on patients affected by channelopathies. This document does not address the indications of genetic testing in patients affected by inherited arrhythmias and their family members.

June 5, 2013—A report of the ACC/AHA Task Force on Practice Guidelines, developed in collaboration with the American College of Chest Physicians, the Heart Rhythm Society, and the International Society for Heart and Lung Transplantation, and endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, this guideline covers multiple management issues for the adult patient with heart failure. 

April 30, 2013—The report expands upon guidelines published in 2005 and a supplemental consensus statement issued by the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) in 2008. The report provides an overview of training, didactic curriculum and research experience, clinical experience, and credentialing/certification.

 This document was reaffirmed on November 28, 2018, and will be formally assessed by November 2023.